Gilead Sciences (GILD) DMA 100 (1992 - 2026)

Gilead Sciences (GILD) DMA 100 (1992 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) DMA 100
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 54.04
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 993.94
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 233.71
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 215.92
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 116.14
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 350.75
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 138.55
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 26.66
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 58.33
10 Novartis Ag 109.78 Bn 109.09 Bn - 152.28

Historic Data

Download Data
DateValue
Jun 5, 2026 138.55
Jun 4, 2026 138.49
Jun 3, 2026 138.41
Jun 2, 2026 138.32
Jun 1, 2026 138.29
May 29, 2026 138.19
May 28, 2026 138.03
May 27, 2026 137.88
May 26, 2026 137.77
May 22, 2026 137.67
May 21, 2026 137.57
May 20, 2026 137.51
May 19, 2026 137.46
May 18, 2026 137.41
May 15, 2026 137.35
May 14, 2026 137.30
May 13, 2026 137.19
May 12, 2026 137.08
May 11, 2026 136.91
May 8, 2026 136.78